Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024

Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024

DelveInsight’s, “Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Gastroesophageal Reflux Disease (GERD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gastroesophageal Reflux Disease (GERD) Understanding

Gastroesophageal Reflux Disease (GERD): Overview

Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus. It is one of the most commonly diagnosed digestive disorders in the US with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs and adversely affects the quality of life. Currently, there is no known cause to explain the development of GERD. Over the years, several risk factors have been identified and implicated in the pathogenesis of GERD. Motor abnormalities such as esophageal dysmotility causing impaired esophageal acid clearance, impairment in the tone of the lower esophageal sphincter (LES), transient LES relaxation, and delayed gastric emptying are included in the causation of GERD. The goals of managing GERD are to address the resolution of symptoms and prevent complications such as esophagitis, BE, and esophageal adenocarcinoma. Treatment options include lifestyle modifications, medical management with antacids and antisecretory agents, surgical therapies, and endoluminal therapies.

""Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastroesophageal Reflux Disease (GERD) pipeline landscape is provided which includes the disease overview and Gastroesophageal Reflux Disease (GERD) treatment guidelines. The assessment part of the report embraces, in depth Gastroesophageal Reflux Disease (GERD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroesophageal Reflux Disease (GERD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Gastroesophageal Reflux Disease (GERD) R&D. The therapies under development are focused on novel approaches to treat/improve Gastroesophageal Reflux Disease (GERD).

Gastroesophageal Reflux Disease (GERD) Emerging Drugs Chapters

This segment of the Gastroesophageal Reflux Disease (GERD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastroesophageal Reflux Disease (GERD) Emerging Drugs

• X842: Cinclus Pharma

X842 represents a novel class of drugs, Potassium Competitive Acid Blocker (P-CAB), and is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion. X842 is a prodrug of the P-CAB linaprazan, developed originally by AstraZeneca. Linaprazan has been evaluated in 23 phase I, and two phase II studies in a total of approximately 2,500 subjects. X842 is being developed for treatment of severe Gastroesophageal reflux disease (GERD) and has the potential to heal esophageal injuries and alleviate GERD symptoms more effectively than current pharmaceutical therapies including PPIs. In comparison, X842 has a longer half-life in the body, shows total control of the gastric acid production, and is tailored for patients with severe eGERD.

• Zastaprazan: Onconic Therapeutics

Zastaprazan is a P-CAB (potassium-competitive acid-blocking) class drug candidate, which is currently replacing existing PPIs (proton pump inhibitors) in the market for peptic ulcer disease, including GERD. Unlike PPI drugs, P-CABs bind directly to potassium ions without the need for activation by stomach acid. It blocks the secretion of gastric acid by interfering with the binding of potassium ions to the proton pump. It can be taken with or without meals and has a longer duration of action than existing therapies, making it highly preferred by both physicians and patients. Meanwhile, in Korea, Onconic began a phase 3 clinical trial for reflux esophagitis for Zastaprazan in January last year. The company expects to launch the drug in Korea by 2024.

Further product details are provided in the report……..

Gastroesophageal Reflux Disease (GERD): Therapeutic Assessment

This segment of the report provides insights about the different Gastroesophageal Reflux Disease (GERD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Gastroesophageal Reflux Disease (GERD)

There are approx. 10+ key companies which are developing the therapies for Gastroesophageal Reflux Disease (GERD). The companies which have their Gastroesophageal Reflux Disease (GERD) drug candidates in the most advanced stage, i.e. Phase III include, Onconic Therapeutics.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Gastroesophageal Reflux Disease (GERD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastroesophageal Reflux Disease (GERD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastroesophageal Reflux Disease (GERD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroesophageal Reflux Disease (GERD) drugs.

Gastroesophageal Reflux Disease (GERD) Report Insights

• Gastroesophageal Reflux Disease (GERD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gastroesophageal Reflux Disease (GERD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gastroesophageal Reflux Disease (GERD) drugs?
• How many Gastroesophageal Reflux Disease (GERD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastroesophageal Reflux Disease (GERD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastroesophageal Reflux Disease (GERD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gastroesophageal Reflux Disease (GERD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cinclus Pharma
• Onconic Therapeutics
• Renexxion
• Addpharma
• Trio Medicines
• Chong Kun Dang Pharmaceutical
• HK inno.N Corporation

Key Products

• X842
• JP-1366
• Naronapride
• AD-214
• AD-213
• AD-212
• Ceclazepide
• CKD-382
• IN-C004
• IN-C005
• IN-C001